ClinicalTrials.gg
CompletedNCT02594384LAM-002A/NHLUpdated Aug 22, 2024Results posted

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

A Phase 1 interventional study of LAM-002A and Rituximab in Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic, sponsored by OrphAI Therapeutics. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-22.

Primary conditionLymphoma, Non-HodgkinRegistry: LymphomaReclassifiedWhy we changed it
Registry
Lymphoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Non-Hodgkin
Why
  1. The study's listed conditions name Lymphoma, Non-Hodgkin, a narrower term within Lymphoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by OrphAI Therapeutics · Phase 1, Interventional, and Treatment

How we know · 11 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.

Enrollment
55th of 171
62 · median 38
Started
2015
with 5 others
Phase 1
26 of 178
2 open now
Registered
154th of 178
by date

Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 55th largest by enrollment of the 171 interventional ones that give a count, is one of 6 that started in 2015, is one of 26 in phase 1, and was the 154th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies testing rituximab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This is a Phase 1 dose-exploration study of LAM-002A administered by mouth in patients with relapsed or refractory B-cell NHL. Safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD),and preliminary anti-tumor activity will be evaluated.

Read the detailed description

LAM-002A is supplied as 25-mg or 50-mg capsules and will be administered two times daily or three times daily by mouth in repeated 28-day cycles. Patients will be advised to take the doses at the same time each day.

A 3 + 3 design will be utilized to define a maximum tolerated dose (MTD). The MTD is defined as the highest dose at which no more than 1 of 6 patients (i.e., \< 33%) experiences a dose-limiting toxicity (DLT) in the dose cohort.

Once the dose and schedule are established, additional patients will be treated to better characterize the safety, tolerability,PK, PD, and anti-tumor activity of LAM-002A when administered alone or in combination with rituximab or atezolizumab.

03

Conditions studied

  • Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic

Keywords

  • Phase 1
  • Safety
  • Apilimod dimesylate
  • Pharmacokinetics
  • Non-Hodgkin Lymphoma
  • Chronic lymphocytic leukemia
04

In context

Lymphoma, Non-Hodgkin Reclassified

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

This study's enrollment of 62 is above the median of 40 across 1,884 interventional studies indexed under Lymphoma, Non-Hodgkin.

Browse Lymphoma, Non-Hodgkin studies →

Lead sponsor

OrphAI Therapeutics is the lead sponsor of 4 studies on the registry; none are open to participants now.

Compared within Lymphoma, Non-Hodgkin, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and comply with the protocol requirements and has signed the document.
  2. Confirmed diagnosis of B-cell Non-Hodgkin's lymphoma limited to follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), primary mediastinal B-cell lymphoma (PMBL), or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that has progressed and for which standard curative measures do not exist or are no longer effective. Prior therapy must have included a rituximab-based regimen.
  3. Patients with DLBCL: Cancer progression after transplant, or be unwilling, unable or not an appropriate candidate for an autologous stem cell or bone marrow transplant
  4. Radiographically measurable lymphadenopathy or extranodal lymphoid (defined as the presence of 1 or more lesions that measure at least 2.0 cm in the longest dimension (as assessed radiographically)
  5. (ECOG) Performance Status of 2 or less.
  6. Adequate organ and marrow function.
  7. Able to swallow oral capsules without difficulty.
  8. Acceptable .
  9. Women of : negative pregnancy test
  10. Adequate archival or fresh tumor tissue (from , bone marrow, or peripheral blood) for analysis of potential predictive biomarkers.

Exclusion criteria

Exclusion Criteria:

  1. Patients with central nervous system (CNS) lymphoma are not eligible for the trial unless the disease had been treated and the subject remains without symptoms with no active CNS lymphoma.
  2. Not recovered from toxicity due to all prior therapies.
  3. Other uncontrolled significant illness.
  4. History of malabsorption or other gastrointestinal (GI) disease that may significantly alter the absorption of LAM-002A
  5. Major surgery within 28 days prior to first dose of study drug.
  6. Past history of tuberculosis (TB) or active infection with TB, (HIV), or .
  7. Lactation or breast feeding.
  8. Unable or unwilling to abide by the study protocol or cooperate fully with the Investigator or designee.

This is a shortened list and additional criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Continuous monotherapy

    All patients will take LAM-002A two times daily by mouth every day until cancer progression or intolerability.

    Drug: LAM-002A

  • Experimental
    Intermittent monotherapy

    All patients will receive LAM-002A at escalating dose levels two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.

    Drug: LAM-002A

  • Experimental
    LAM-002A + rituximab

    All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab 375 mg/m2 by vein every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions)

    Drug: Rituximab

  • Experimental
    LAM-002A + atezolizumab

    All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability

    Drug: Atezolizumab

Interventions

07

What researchers measure

Primary outcomes

  1. Determination of the Maximum Tolerated Dose (MTD) of Continuous Oral LAM-002A

    MTD was determined by testing increasing doses up to 125 mg twice a day or 75 mg three times a day orally on dose escalation cohorts with 3 to 6 participants each. In the dose escalation, the cohort sizes of 3 to 6 subjects allow evaluation of regimen safety using a standard definition of MTD (ie, the highest starting dose associated with DLT in \<33% of subjects during the first cycle of therapy) when administered continuously (daily administration) and then when administered intermittently (repeated courses of 3 days on and 4 days off).

    Time frame: 28 days

Secondary outcomes

  1. Peak Plasma Concentration (Cmax) of LAM-002A

    Evaluation of the peak plasma concentration (Cmax) of LAM-002A and its metabolites in plasma on Day 1 and Day 8.

    Time frame: 8 days

  2. Area Under the Plasma Concentration Versus Time Curve (AUC) of LAM-002A

    Evaluation of the Area under the concentration-time curve from time-zero to the time of the last quantifiable concentration (AUClast) of LAM-002ALAM-002A and its metabolites in plasma on Day 1 and Day 8.

    Time frame: 8 days

  3. Objective Response Rate

    Anti-tumor response as assessed by investigator according to modified Hallek or Lugano Response Criteria by Disease Type and Cohort

    Time frame: 1 cycle (28 days) up to a maximum of 24 cycles

08

Results

Posted Aug 22, 2024
Limitations and caveats
Participants receiving LAM-002A with a regimen of 125 mg BID were accrued to both dose escalation (N=6) and then dose expansion (N=14), the results for the combined total (N=20) for this group is presented. Additionally, a MTD for the intermittent dosing regimen (3 days on and 4 days off every 7 days) was not established due to the shift of the trial to the dose expansion (monotherapy or combination therapy); the intermittent regimen was not further pursued after 3 subjects had been accrued.

Participant flow

This study was conducted at 12 study centers in the United States, 11 of which enrolled subjects to the trial.

Participant flow — Overall Study
MilestoneLAM-002A Continuous Monotherapy - 50 mg BIDLAM-002A Continuous Monotherapy - 100 mg BIDLAM-002A Continuous Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 75 mg TIDLAM-002A Intermittent Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 125 mgLAM-002A + RituximabLAM-002A + Atezolizumab
Started3854320127
Completed00000130
Not completed385431997
Withdrew: Disease progression370221255
Withdrew: Adverse event01410611
Withdrew: Withdrawal by subject00010001
Withdrew: Physician decision00000120
Withdrew: Progressive leukocytosis00100000
Withdrew: Lack of efficacy00001000
Withdrew: Substantial noncompliance00000010

Outcome measures

PrimaryDetermination of the Maximum Tolerated Dose (MTD) of Continuous Oral LAM-002A

MTD was determined by testing increasing doses up to 125 mg twice a day or 75 mg three times a day orally on dose escalation cohorts with 3 to 6 participants each. In the dose escalation, the cohort sizes of 3 to 6 subjects allow evaluation of regimen safety using a standard definition of MTD (ie, the highest starting dose associated with DLT in \<33% of subjects during the first cycle of therapy) when administered continuously (daily administration) and then when administered intermittently (repeated courses of 3 days on and 4 days off).

Time frame:
28 days
Reported as:
Number · mg BID
Determination of the Maximum Tolerated Dose (MTD) of Continuous Oral LAM-002A
mg BIDAll Participants
Determination of the Maximum Tolerated Dose (MTD) of Continuous Oral LAM-002A125
SecondaryPeak Plasma Concentration (Cmax) of LAM-002A

Evaluation of the peak plasma concentration (Cmax) of LAM-002A and its metabolites in plasma on Day 1 and Day 8.

Time frame:
8 days
Reported as:
Mean · ng/mL
Peak Plasma Concentration (Cmax) of LAM-002A
ng/mLLAM-002A Continuous Monotherapy - 50 mg BIDLAM-002A Continuous Monotherapy - 75 mg TIDLAM-002A Continuous Monotherapy - 100 mg BIDLAM-002A Continuous Monotherapy - 125 mg BIDLAM-002A Continuous Monotherapy - 150 mg BIDLAM-002A Intermittent Monotherapy - 150 mg
Apilimod - Day 1117 ± 69.6158 ± 61.6263 ± 168207 ± 82.4243 ± 76.1280 ± 135
Apilimod - Day 8140 ± 95.1339 ± 215331 ± 273331 ± 287369 ± 90.5108
STA-5908 - Day 1112 ± 85.0114 ± 71.6215 ± 88.6144 ± 92.5196 ± 142207 ± 135
STA-5908 - Day 8103 ± 43.7239 ± 195278 ± 137234 ± 173240 ± 99.7113
STA-5944 - Day 1209 ± 145243 ± 124346 ± 131281 ± 125369 ± 306466 ± 247
STA-5944 - Day 8188 ± 101436 ± 334439 ± 215383 ± 225391 ± 9.90260
STA-6048 - Day 163.2 ± 40.259.9 ± 54.0136 ± 64.290.0 ± 58.6131 ± 134145 ± 66.0
STA-6048 - Day 860.6 ± 32.0154 ± 113161 ± 43.0122 ± 81.7116 ± 87.4140
SecondaryArea Under the Plasma Concentration Versus Time Curve (AUC) of LAM-002A

Evaluation of the Area under the concentration-time curve from time-zero to the time of the last quantifiable concentration (AUClast) of LAM-002ALAM-002A and its metabolites in plasma on Day 1 and Day 8.

Time frame:
8 days
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration Versus Time Curve (AUC) of LAM-002A
h*ng/mLLAM-002A Continuous Monotherapy - 50 mg BIDLAM-002A Continuous Monotherapy - 75 mg TIDLAM-002A Continuous Monotherapy - 100 mg BIDLAM-002A Continuous Monotherapy - 125 mg BIDLAM-002A Continuous Monotherapy - 150 mg BIDLAM-002A Intermittent Monotherapy - 150 mg BID
Apilimod - Day 1238 ± 88.1583 ± 290515 ± 221562 ± 234700 ± 290777 ± 437
Apilimod - Day 8374 ± 1191040 ± 4831130 ± 9301290 ± 10401060 ± 85.7563
STA-5944 - Day 1542 ± 2141020 ± 6591120 ± 5501180 ± 5871590 ± 14201700 ± 843
STA-5944 - Day 8653 ± 3652070 ± 14301810 ± 12401860 ± 11601320 ± 2111350
STA-5908 - Day 1312 ± 156526 ± 291762 ± 371625 ± 419936 ± 734968 ± 547
STA-5908 - Day 8433 ± 1951140 ± 8181360 ± 7961270 ± 8751040 ± 572690
STA-6048 - Day 1238 ± 91.2280 ± 216622 ± 372443 ± 325785 ± 923869 ± 415
STA-6048 - Day 8308 ± 1641040 ± 780959 ± 343746 ± 509556 ± 397760
SecondaryObjective Response Rate

Anti-tumor response as assessed by investigator according to modified Hallek or Lugano Response Criteria by Disease Type and Cohort

Time frame:
1 cycle (28 days) up to a maximum of 24 cycles
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsLAM-002A Continuous Monotherapy - 50 mg BIDLAM-002A Continuous Monotherapy - 100 mg BIDLAM-002A Continuous Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 75 mg TIDLAM-002A Intermittent Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 125 mgLAM-002A + RituximabLAM-002A + Atezolizumab
DLBCL (diffuse large B-cell lymphoma)00000000
FL (follicular lymphoma)00000252
MZL (marginal zone lymphoma)00000010
MCL (mantle cell lymphoma)00000000
CLL/SLL (chronic lymphocytic leukemia/ small lymphocytic lymphoma)00000000

Adverse events

Collected over Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LAM-002A Continuous Monotherapy - 50 mg BID0/3 (0%)0/3 (0%)3/3 (100%)
LAM-002A Continuous Monotherapy - 100 mg BID1/8 (12.5%)3/8 (37.5%)8/8 (100%)
LAM-002A Continuous Monotherapy - 150 mg BID1/5 (20%)1/5 (20%)5/5 (100%)
LAM-002A Continuous Monotherapy - 75 mg TID0/4 (0%)2/4 (50%)4/4 (100%)
LAM-002A Intermittent Monotherapy - 150 mg BID0/3 (0%)0/3 (0%)3/3 (100%)
LAM-002A Continuous Monotherapy - 125 mg BID3/20 (15%)9/20 (45%)20/20 (100%)
LAM-002A + Rituximab0/12 (0%)5/12 (41.7%)12/12 (100%)
LAM-002A + Atezolizumab3/7 (42.9%)6/7 (85.7%)7/7 (100%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventLAM-002A Continuous Monotherapy - 50 mg BIDLAM-002A Continuous Monotherapy - 100 mg BIDLAM-002A Continuous Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 75 mg TIDLAM-002A Intermittent Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 125 mg BIDLAM-002A + RituximabLAM-002A + Atezolizumab
Febrile neutropeniaBlood and lymphatic system disorders0/31/80/51/40/30/200/121/7
Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/80/51/40/30/200/120/7
SyncopeNervous system disorders0/30/80/51/40/30/200/120/7
HypoxiaRespiratory, thoracic and mediastinal disorders0/30/80/51/40/30/200/120/7
HypotensionVascular disorders0/30/80/51/40/30/200/120/7
Lung infectionRespiratory, thoracic and mediastinal disorders0/30/81/50/40/30/200/120/7
Tumour lysis syndromeMetabolism and nutrition disorders0/30/80/50/40/30/202/120/7
ColitisGastrointestinal disorders0/30/80/50/40/30/200/121/7
NauseaGastrointestinal disorders0/30/80/50/40/30/200/121/7
Disease progressionGeneral disorders0/31/80/50/40/31/200/121/7
Most frequent other events
Showing 10 of 228
Most frequent other events
EventLAM-002A Continuous Monotherapy - 50 mg BIDLAM-002A Continuous Monotherapy - 100 mg BIDLAM-002A Continuous Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 75 mg TIDLAM-002A Intermittent Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 125 mg BIDLAM-002A + RituximabLAM-002A + Atezolizumab
NauseaGastrointestinal disorders0/33/83/53/40/39/206/126/7
VomitingGastrointestinal disorders0/31/83/53/40/34/203/124/7
ConstipationGastrointestinal disorders0/32/80/52/41/33/201/125/7
DiarrhoeaGastrointestinal disorders1/30/82/52/42/36/206/121/7
InsomniaPsychiatric disorders0/31/82/51/42/31/200/122/7
Electrocardiogram QT prolongedInvestigations0/30/83/51/40/30/200/120/7
FatigueGeneral disorders0/34/82/52/41/310/207/121/7
Oedema peripheralGeneral disorders1/31/80/52/40/33/202/121/7
Hemoglobin decreasedInvestigations0/33/80/52/40/35/200/121/7
Blood creatinine increasedInvestigations0/30/81/52/40/32/201/121/7

Baseline characteristics

Full analysis set=All subjects who received ≥1 dose of study drug.

Age, Customized
Age, Customized(Participants)LAM-002A Continuous Monotherapy - 50 mg BIDLAM-002A Continuous Monotherapy - 100 mg BIDLAM-002A Continuous Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 75 mg TIDLAM-002A Intermittent Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 125 mgLAM-002A + RituximabLAM-002A + AtezolizumabTotal
Age Category — <65 years2310097224
Age Category — ≥65 years15443115538
Sex: Female, Male
Sex: Female, Male(Participants)LAM-002A Continuous Monotherapy - 50 mg BIDLAM-002A Continuous Monotherapy - 100 mg BIDLAM-002A Continuous Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 75 mg TIDLAM-002A Intermittent Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 125 mgLAM-002A + RituximabLAM-002A + AtezolizumabTotal
Female1542294330
Male23121118432
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LAM-002A Continuous Monotherapy - 50 mg BIDLAM-002A Continuous Monotherapy - 100 mg BIDLAM-002A Continuous Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 75 mg TIDLAM-002A Intermittent Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 125 mgLAM-002A + RituximabLAM-002A + AtezolizumabTotal
Race — White364331611753
Race — Black/African American010101104
Race — Other011003005
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LAM-002A Continuous Monotherapy - 50 mg BIDLAM-002A Continuous Monotherapy - 100 mg BIDLAM-002A Continuous Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 75 mg TIDLAM-002A Intermittent Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 125 mgLAM-002A + RituximabLAM-002A + AtezolizumabTotal
Ethnicity — Not Hispanic/Latino385331612757
Ethnicity — Hispanic/Latino000104005
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)LAM-002A Continuous Monotherapy - 50 mg BIDLAM-002A Continuous Monotherapy - 100 mg BIDLAM-002A Continuous Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 75 mg TIDLAM-002A Intermittent Monotherapy - 150 mg BIDLAM-002A Continuous Monotherapy - 125 mgLAM-002A + RituximabLAM-002A + AtezolizumabTotal
0, fully active, able to carry on all predisease performance without restrictions0511173018
1, restricted in physically strenuous activity but ambulatory and able to do light or sedentary work33322119639
2, ambulatory and capable of all self-care but unable to work. Up more than 50% of waking hours001102004
3, capable of only limited self-care, confined to bed or chair more than 50% of waking hours000000011
09

Study locations

11 sites
  • Clearview Cancer Institute
    Huntsville, Alabama 35805, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Winship Cancer Institute at Emory University
    Atlanta, Georgia 30322, United States
  • Horizon Oncology Research, Inc.
    Lafayette, Indiana 47905, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • New York University School of Medicine
    New York, New York 10016, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Mar 2020 and a completion of Mar 2023. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2024, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2015
First posted
Nov 3, 2015
Start
Oct 2015
Primary completionActual
Mar 9, 2020
CompletionActual
Mar 30, 2023
Results first posted
Aug 22, 2024
Last update
Aug 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02594384
Lead sponsor
OrphAI Therapeutics
Responsible party
Sponsor
First posted
Nov 3, 2015
Start date
Oct 2015
Primary completion
Mar 9, 2020
Completion
Mar 30, 2023
Results posted
Aug 22, 2024
Last update
Aug 22, 2024

Study contacts

Langdon Miller, MD
study director · AI Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Apilimod Dimesylate Capsule · Rituximab

Start the discussion